Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer
Immuneering Corporation (NASDAQ:IMRX) is a clinical-stage oncology company headquartered in Cambridge, Massachusetts, that is pioneering a new class…
Browsing Tag